Quantcast

Latest Diabetic foot Stories

2009-03-20 08:30:00

-- Accepted Abstract on CellerateRx Conducted by Dr. Matt Regulski -- FORT WORTH, Texas, March 20 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is exhibiting at DFCon 09 on March 19-21, 2009 at the Renaissance Hollywood Hotel in Los Angeles, California. DFCon is considered the premier international multidisciplinary diabetic foot conference that attracts attendees from more than...

2009-03-18 07:00:00

ADDISON, Texas, March 18 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex(TM) Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting in Los Angeles, CaliforniaMarch 19-21. The work will be presented on posters that will be on display during the meeting. Clinical evidence will be presented on a poster titled, "Nanoparticulate...

2009-03-13 16:25:00

ADDISON, Texas, March 13 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Chairman of the Company's Scientific Advisory Board. Currently, Dr. Jeffrey Niezgoda is the Medical Director of The Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. Luke's Medical Center, Aurora Health Care, in Milwaukee, Wisconsin. He also serves as the President and Chief Operating Officer of...

2009-02-13 06:30:00

Eleven of eleven wounds healed in 6 weeks or less PRINCETON, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that its MEDIHONEY Dressings were the focus of a case series on eleven non-healing venous leg ulcers. These wounds had previously failed to heal while being managed with such therapeutic modalities as multi-layered compression, silver antimicrobial dressings, antibiotic therapy, and...

2008-11-03 12:00:26

PRINCETON, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (BULLETIN BOARD: DSCI) announced today the first study patient has been entered into the company's Phase II study of its drug candidate, DSC127. Enrollment of the 75-patient study, looking into the drug's ability to accelerate healing in diabetic foot ulcers, is expected to be completed within 12 months. Currently, 4 US facilities have signed on as clinical study sites, with an additional 15 sites pending contract...

2008-10-30 06:00:44

BETHESDA, Md., Oct. 30 /PRNewswire-USNewswire/ -- Nearly 246 million people across the globe battle diabetes and its complications every year. However, medical care for diabetes is often not sought in time to prevent serious amputations, according to a recent survey by the American Podiatric Medical Association (APMA). The APMA study, conducted by an independent research firm, found that 25 percent of the 600 people surveyed who had suffered an amputation from diabetes said they should...

2008-10-09 09:00:52

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), today provided a clinical and business update on recent developments and activities. "Oculus continues to make progress both in developing its commercial business and advancing the Microcyn(R) Technology platform via the U.S. clinical program," said Hoji Alimi, CEO of Oculus. Recent highlights and upcoming events include: -- The company's clinical team held a successful End-of-Phase-II meeting with the Food and Drug Administration...

2008-09-04 09:00:08

Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced that the company held a successful End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) on August 29, 2008. Following a review of the Phase II data on Microcyn(R) Technology for the treatment of mildly infected diabetic foot ulcers, the FDA agreed: -- Oculus may move forward into the pivotal phase of its U.S. clinical program for Microcyn Technology. -- There were no safety issues relative to moving...

2008-08-28 12:01:22

Derma Sciences, a provider of advanced wound care products, has signed an agreement with MedEfficiency for the exclusive distribution of the company's novel total contact casts. According to MedEfficiency, the TCC-EZ cast will act as a protective barrier for the open wounds that often develop on the undersides of diabetic patients' feet, and help to greatly reduce the over 80,000 diabetes-related lower extremity amputations that are performed annually in the US, at a cost of over $2.5...

2008-08-12 09:01:36

Immunosyn Corporation (OTCBB:IMYN) announced today that marketing, distribution and patient treatment approval has been granted by the Ministry of Health Malaysia for SF-1019 in the Private Pay Heath Sector in Malaysia. The marketing name for SF-1019 in Malaysia will be R-1818. Argyll Biotechnologies, LLC, the licensor of SF-1019, Immunosyn's strategic partner and its largest shareholder, has notified Immunosyn that the Ministry of Health Malaysia has approved the importation, marketing...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related